Related Experiment Video
Updated: Mar 3, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Respiratory Biologics Utilization, Prescription Predictors, and Outcomes in Patients With Asthma and Comorbid
Dinah Foer1, Diane L Seger2, Julie Fiskio3
1Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, Mass.
Background:
Patients with asthma and elevated body mass index have higher baseline exacerbation risk and vulnerability to corticosteroid adverse effects. Yet evidence on the use and efficacy of respiratory biologics, which reduce these risks, in patients with obesity is lacking.
Objective:
To test the hypothesis that respiratory biologics are underused in eligible patients with obesity.
Methods:
This is a retrospective observational analysis of adult patients with active, moderate to severe asthma and with a body mass index of 25 kg/m2 or greater in the electronic health records of a large US health system (2018-2023). We included patients meeting US Food and Drug Administration-specified eligibility criteria. Primary outcomes were biologic prescription and time to prescription. Secondary outcomes were change in exacerbation rates and factors associated with biologic prescription. Exploratory outcomes were biologic eligibility using obesity-adjusted eosinophil counts (≥ 96cells/μL) and use compared with a healthy weight cohort.
Results:
We included 5,805 patients with asthma and overweight or obesity who were eligible for a biologic. Of these, 11.9% were prescribed biologics. Of the biologic-eligible cohort, 59.8% had obesity and 10.4% of those patients were prescribed biologics. In adjusted analyses, obesity reduced prescription odds and time to initiation. Subspecialist care was the strongest prescription predictor. Annualized exacerbation rates significantly declined across type 2 biologics users with obesity. Use of obesity-adjusted eosinophil criteria expanded biologics eligibility by 11.3% without clear exacerbation benefit.
Conclusions:
Only a fraction of eligible patients with asthma and comorbid obesity receive biologics despite meeting type 2 biomarker criteria, compared with patients with overweight or healthy weight. These data may substantially inform health services research and therapeutic interventions to improve asthma management.
More Related Videos
08:30Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
Published on: March 15, 2018
05:10Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: